{"id":"NCT02613871","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection","officialTitle":"A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-22","primaryCompletion":"2017-01-04","completion":"2018-11-07","firstPosted":"2015-11-25","resultsPosted":"2018-02-13","lastUpdate":"2020-03-06"},"enrollment":111,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection"],"interventions":[{"type":"DRUG","name":"LDV/SOF","otherNames":["HarvoniÂ®","GS-5885/GS-7977"]}],"arms":[{"label":"LDV/SOF","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with chronic genotype 1 or 2 HCV infection who are coinfected with HBV in Taiwan.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"LDV/SOF FDC","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":8,"countries":["Taiwan"]},"refs":{"pmids":["29174546","34864948"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":111},"commonTop":["Headache","Upper respiratory tract infection","Fatigue"]}}